National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Burosumab (Crysvita®) for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.

 

NCPE Assessment Process Complete
Rapid review commissioned 22/11/2018
Rapid review completed 21/12/2018
Rapid Review outcome A full HTA is recommended